CAR T-cell remedy is used to deal with sufferers with blood cancers resembling a number of myeloma. Since it could trigger critical unwanted side effects, sufferers are normally hospitalized and monitored for as much as two weeks after remedy. With therapies usually solely supplied at massive most cancers facilities, they are often tough to entry for a lot of sufferers. Be a part of Dr. Sridevi Rajeeve, Myeloma and Cell Remedy Oncologist at Memorial Sloan Kettering Most cancers Heart, and Todd Greenwood, Senior Director of Proof and Outcomes at ZS Associates, as they focus on how wearable distant affected person monitoring gadgets might change the way in which this remedy is obtainable.
You’ll study extra about:
- CAR T-cell remedy dangers and the challenges introduced by the standard means the remedy is obtainable
- Outcomes of scientific trials performed utilizing wearable distant affected person monitoring gadgets
- How distant affected person monitoring might make CAR T-cell remedy extra accessible and cost-effective
